Compare AbCellera Biologics Inc (ABCL) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Diageo plc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Diageo plc trades at $81.16 (market cap $45.92B). The key difference: Diageo plc is far larger — about 19.5× AbCellera Biologics Inc's market cap, and Diageo plc pays a 4.01% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DEO | |
|---|---|---|
Market Cap | $2.35B | $45.92B |
Sector | Health | Technology |
52-Week High | $8.12 | $115.33 |
52-Week Low | $2.78 | $72.47 |
Enterprise Value | $1.99B | $66.74B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Diageo (DEO) trades at $81.67, down 0.6% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 12.19% net margin and 22.29% ROE, but faces headwinds in the US spirits market. Recent news highlights CEO Dave Lewis's upcoming strategy update amid concerns over US demand and promotional pressures.
The outlook is cautious with analyst consensus leaning buy (48.65%) but significant hold ratings (43.24%). Key risks include US market weakness and shifting consumer trends, while opportunities lie in premiumization and innovation. The stock's valuation at a P/E of 18.87 appears reasonable if recovery initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
